Arch Biopartners Trial Commences Patient Dosing

Arch Biopartners Inc. announced that St. Michael's Hospital has begun patient dosing in its Phase II clinical trial for LSALT Peptide, targeting the condition known as CS-AKI. This marks a critical step forward in the development of the company's therapeutic candidate. The commencement of patient dosing signifies the transition from preclinical research to human trials, a crucial phase for evaluating the safety and efficacy of the LSALT Peptide. Arch Biopartners is focused on advancing this promising treatment through rigorous clinical evaluation.